Neoadjuvant Chemoradiation With Tegafur in Cancer of the Pancreas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant Chemoradiation With Tegafur in Cancer of the Pancreas

Published:2004-08 Issue:4 Volume:27 Page:343-349
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:American Journal of Clinical Oncology

Author:

Calvo Felipe A.,Matute Raúl,García-Sabrido José Luis,Gómez-Espí Marina,Martínez Nuria E.,Lozano Miguel A.,Herranz Rafael

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference32 articles.

1. Pharmacokinetics of ftorafur after intravenous and oral administration

2. Pathologic downstaging of T3–4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur

3. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer

4. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

5. Phase II study of radiochemotherapy with uft and low-dose oral leucovorin in patients with unresectable rectal cancer

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas;JAMA Oncology;2022-09-01

2. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer;Pancreas;2022-03

3. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades;Annals of Hepato-Biliary-Pancreatic Surgery;2021-05-31

4. Pathological complete response after neoadjuvant therapy for pancreatic ductal adenocarcinoma does not equal cure;ANZ Journal of Surgery;2021-02-26

5. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?;Journal of Clinical Medicine;2021-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3